Metacel Pharmaceuticals’ Ozobax (baclofen) Receives the US FDA’s Approval for Spasticity Due to Multiple Sclerosis

 Metacel Pharmaceuticals’ Ozobax (baclofen) Receives the US FDA’s Approval for Spasticity Due to Multiple Sclerosis

Metacel Pharmaceuticals’ Ozobax (baclofen) Receives the US FDA’s Approval for Spasticity Due to Multiple Sclerosis

Shots:

  • Ozabax is a gamma-aminobutyric acid (GABA-ergic) agonist orally administered low dosage and is available as a 5mg/5 ml oral solution
  • The efficacy of Ozobax is based on the bioavailability study evaluated in healthy adults in comparison with Baclofen oral tablets
  • Metacel is also planning to launch Ozobax with pending plans. Ozobax has a warning of for its withdrawal can lead to neonatal withdrawal symptoms, drowsiness and sedation, poor tolerability in stroke patients, schizophrenia, or confusional states, and ovarian cysts

Click here to­ read full press release/ article | Ref: OptumRx | Image: Twitter

Shiwani Sharma

Shiwani Sharma is a Senior Editor at PharmaShots. She has in-depth knowledge of lifesciences industry including pharma and biotech sectors. She also covers news in field of Digital Health, Medtech and regulatory approvals from the US FDA, EU, and other global regulatory bodies in the industry. Additionally, she also writes Whitepapers, analysis reports, blogs on pharma and biotech industry. She is graduate in Biotechnology. She can be contacted on shiwani@pharmashots.com

Related post